Resveratrol Quercetin Curcumin Composition Inhibiting Platelet Aggregation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Microvascular diseases, such as Alzheimer's disease and glaucoma, are associated with abnormal platelet function, leading to obstructive clotting or bleeding issues, and existing treatments do not effectively inhibit superactivated platelets (SAPs) which contribute to these conditions.

Innovation Solution

A composition comprising a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist, preferably resveratrol, quercetin, and curcumin or naltrexone, is administered to inhibit SAP aggregation, thereby addressing the abnormal platelet function in microvascular diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used, then general platelet function is addressed, but superactivated platelets (SAPs) are not effectively inhibited

Engineering Contradiction:

Improveeffectiveness of platelet inhibitionVSAvoidability to target SAPs specifically

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by designing a composition that specifically targets superactivated platelets (SAPs) with distinct pharmacological properties. The combination of aspirin, clopidogrel, and dipyridamole creates a localized effect on SAPs while preserving normal platelet function, thereby resolving the contradiction between general platelet inhibition effectiveness and specific SAP targeting capability.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by modifying the pharmacological parameters of platelet inhibition through a multi-component regimen. By adjusting the dosing and combination of aspirin, clopidogrel, and dipyridamole, the treatment achieves selective inhibition of SAPs based on their enhanced procoagulant activity, thus improving reliability for SAP inhibition while maintaining adaptability to different platelet activation states.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If platelet aggregation is inhibited to prevent thrombus formation, then thrombotic events are reduced, but bleeding risk increases

Engineering Contradiction:

Improvethrombus formationVSAvoidbleeding

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent applies partial action by using a combination of antiplatelet agents at optimized doses that provide sufficient inhibition of pathological thrombus formation while avoiding excessive suppression of normal hemostasis. The multi-component regimen allows for partial inhibition of platelet aggregation specifically in superactivated platelets, reducing thrombotic events without proportionally increasing bleeding risk.

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The patent introduces intermediary mechanisms through the specific combination of aspirin, clopidogrel, and dipyridamole, which act on different platelet activation pathways. This multi-pathway approach creates intermediary control points that allow selective inhibition of SAPs while preserving normal platelet function, thereby mitigating the harmful effect of bleeding while still preventing thrombus formation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination effectively reduces SAP levels, treating microvascular diseases by inhibiting platelet aggregation and preventing thrombus formation, and is applicable in various surgical contexts and conditions like deep vein thrombosis and myocardial infarction.

Implementation Method 1

Superactivated platelet (SAP) aggregation in a patient is inhibited by administering to a subject in need of such inhibition an effective amount of a composition which comprises as active ingredients a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist

Methodology Applied

Scientific EffectPlatelet aggregation inhibition:

Data Source

PatentUS11234942B2Composition and method for inhibiting platelet aggregation

Publication Date: 2022.02.01 KNEPPER PAUL A

AI summary

Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a TLR4/MD2 receptor antagonist such as naltrexone or curcumin inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.